Desley van Zoggel

Impact of metastases on survival 95 CHAPTER 5 References 1. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422. 2. Van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:1762–1769. 3. Kok END, Havenga K, Tanis PJ, et al. Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer. Br J Surg. 2020;107:537–545. 4. Dresen RC, Gosens MJ, Martijn H, et al. Radical Resection After IORT-Containing Multimodality Treatment is the Most Important Determinant for Outcome in Patients Treated for Locally Recurrent Rectal Cancer. Ann Surg Oncol. . Epub ahead of print 2008. DOI: 10.1245/s10434-0089896-z. 5. Alberda WJ, Verhoef C, Schipper MEI, et al. The Importance of a Minimal Tumor-Free Resection Margin in Locally Recurrent Rectal Cancer. Dis Colon Rectum. 2015;58:677–685. 6. Bosman SJ, Holman FA, Nieuwenhuijzen GAP, et al. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg. 2014;101:1280–1289. 7. NielsenMB, Laurberg S, HolmT. Current management of locally recurrent rectal cancer. Colorectal Disease. 2011;13:732–742. 8. van Zoggel DMGI, Bosman SJ, Kusters M, et al. Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer. Br J Surg. 2018;105:447–452. 9. Voogt ELK, vanZoggel DMGI, KustersM, et al. ImprovedOutcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer. Ann Surg Oncol. 2020;8–11. 10. van den Brink M, Stiggelbout AM, van den Hout WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22:3958–3964. 11. Detering R, Karthaus EG, Borstlap WAA, et al. Treatment and survival of locally recurrent rectal cancer: A cross-sectional population study 15 years after the Dutch TME trial. Eur J Surg Oncol. 2019;45:2059–2069. 12. Hagemans JAW, vanRees JM, AlberdaWJ, et al. Locally recurrent rectal cancer; long-termoutcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol. 2020;46:448–454. 13. MartinT, Ye L, Sanders A, et al. Cancer invasion andmetastasis: molecular and cellular perspective. In: Madam Curie Bioscience Database. Austin (TX): Landes Bioscience:2000–2013. 14. Leong L. Clinical relevance of targeting cancer metastases. In: MadamCurie Bioscience Database. Austin (TX): Landes Bioscience:8–10. 15. Kishan AU, Voog JC, Wiseman J, et al. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. Br J Radiol.;90 . Epub ahead of print 2017. DOI: 10.1259/BJR.20170134. 16. Schurr P, Lentz E, Block S, et al. Radical redo surgery for local rectal cancer recurrence improves overall survival: a single center experience. J Gastrointest Surg. 2008;12:1232–1238. 17. Cyr DP, Zih FS, Wells BJ, et al. Long-term outcomes following salvage surgery for locally recurrent rectal cancer: A 15-year follow-up study. Eur J Surg Oncol. 2020;46:1131–1137.